

# Renal, Ocular, and Neuromuscular Involvements in Patients with *CLDN19* Mutations

Stanislas Faguer,<sup>\*,††</sup> Dominique Chauveau,<sup>\*,††</sup> Pascal Cintas,<sup>\*,§</sup> Ivan Tack,<sup>\*,#</sup> Olivier Cointault,<sup>†</sup> Lionel Rostaing,<sup>†,††</sup> Rosa Vargas-Poussou,<sup>\*,†††</sup> and David Ribes<sup>†</sup>

## Summary

**Background and objectives** The objective of this study was to describe the renal and extrarenal findings in patients with recessively inherited familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) associated with *CLDN19* mutations.

**Design, setting, participants, & measurements** Medical records of three patients from two French unrelated families with *CLDN19* mutations were retrospectively examined.

**Results** Direct sequencing of *CLDN19* identified a known variant (p.Gly20Asp) in all patients and a new missense mutation (p.Val44Met) in one (compound heterozygous). The patients' renal phenotype closely mimicked *CLDN16*-related nephropathy: low serum Mg<sup>2+</sup> (<0.65 mmol/L) despite oral supplementation, hypercalciuria partly thiazide-sensitive, and progressive renal decline with ESRD reached at age 16 and 22 years in two individuals. Primary characteristics (failure to thrive, recurrent urinary tract infections, or abdominal pain), age at onset (0.8 to 16 years), and rate of renal decline were highly heterogeneous. Ocular involvement was identified in all patients, although two patients did not have visual loss. Additionally, exercise intolerance with pain, weakness, and electromyographical alterations mimicking a Ca<sup>2+</sup>/K<sup>+</sup> channelopathy (pattern V) were observed in two of three individuals. These features persisted despite the normalization of serum K<sup>+</sup> and Mg<sup>2+</sup> after renal transplantation.

**Conclusions** Ocular manifestations, even subtle, and exercise intolerance mimicking mild to moderate periodic paralysis are two symptoms that need to be searched for in patients with FHHNC and may indicate *CLDN19* mutations.

*Clin J Am Soc Nephrol* 6: 355–360, 2011. doi: 10.2215/CJN.02870310

## Introduction

Nephrocalcinosis is a histologic condition defined by an increase in kidney calcium content, which can be easily identified by an abdominal radiography or a computed tomography scan. It relies on a broad spectrum of etiologies that can be separated into hypercalcemic states of various origin or specific inherited tubular disorders (1).

Among the genetic causes of nephrocalcinosis, familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is a rare tubulopathy with recessive inheritance. Most patients with FHHNC harbor a mutation in the *CLDN16* gene, which encodes for claudin-16 (OMIM248250) (2–4). Also, mutations of *CLDN19*, which encodes for claudin-19, have been identified in a subgroup of FHHNC patients with severe ocular involvement (OMIM248190) (5). In mice kidneys, claudin-16 and claudin-19 are expressed in the medullary and cortical thick ascending limb of the loop of Henle (5), where they are colocalized to tight junction proteins and form a cation-selective complex (6). Although their role remains poorly understood (7,8), they probably modulate the passive paracellular magnesium (Mg<sup>2+</sup>) and calcium

(Ca<sup>2+</sup>) transport in these tubular segments, which is driven by an electrical gradient resulting from potassium (K<sup>+</sup>) exit across apical membranes through the renal outer-medullary K<sup>+</sup> channel and chloride (Cl<sup>-</sup>) and sodium (Na<sup>+</sup>) exit across basal membranes through the Cl<sup>-</sup> channel and Na<sup>+</sup>-K<sup>+</sup>-ATPase, respectively (9).

The renal phenotype associated with *CLDN19* mimics *CLDN16* mutations (5,10). It encompasses renal Mg<sup>2+</sup> and Ca<sup>2+</sup> wasting, leading to hypomagnesemia, nephrocalcinosis, and progressive renal decline. FHHNC may be disclosed by a wide variety of symptoms, including recurrent urinary tract infection, polyuria and/or polydipsia, nephrolithiasis, or tetanic convulsions (11). In patients with *CLDN16* mutations, progression to ESRD may be predicted by the genotype (12). Of note, Konrad *et al.* emphasized the severe ocular involvement (macular colobomata, nystagmus, myopia, visual loss) shown in *CLDN19* contrasting with the mild ocular involvement in some *CLDN16* patients (myopia, astigmatism, hypermetropia, strabismus) (5,10).

In this study, we describe the renal and extrarenal features from three patients with *CLDN19* mutations

\*Service de Néphrologie et Immunologie Clinique, Centre de Référence des Maladies Rénales Rares, CHU Toulouse, France; <sup>†</sup>INSERM, CHU Toulouse, France; <sup>‡</sup>Université Paul Sabatier 3, Toulouse, France; <sup>§</sup>Centre de Référence de Pathologie Neuromusculaire, CHU Toulouse, France; <sup>||</sup>Service des Explorations Fonctionnelles Rénales, CHU Toulouse, France; <sup>¶</sup>Service de Néphrologie, Hypertension, Dialyse et Transplantation d'Organes, CHU Toulouse, France; <sup>\*\*</sup>Département de Génétique, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges-Pompidou, Paris, France; and <sup>††</sup>Centre de Référence des Maladies Rénales Héritaires de l'Enfant et de l'Adulte, MARHEA, Paris, France

**Correspondence:** Dr. Stanislas Faguer, Service de Néphrologie et Immunologie Clinique, Hôpital de Rangueil, 1 Avenue Jean Poulhès, TSA 50032, 31059 Toulouse Cedex 9, France. Phone: 33-5-6132-3282; Fax: 33-5-6132-2775; E-mail: stanislas.faguer@inserm.fr

and suggest that intolerance to muscular exercise mimicking periodic paralysis may be part of the clinical spectrum associated with *CLDN19* mutations.

## Patients

We report three female patients, from two nonconsanguineous families, with FHHNC and *CLDN19* mutations followed in two nephrology units in a university hospital in Toulouse in southwest France. Clinical characteristics and genotypes are presented in Table 1.

First symptoms (failure to thrive, urolithiasis with urinary tract infection, and abdominal pain) occurred from 0.9 to 16 years of age. Renal symptoms included recurrent urolithiasis, urinary tract infection, and/or polyuria-polydipsia. Concomitant bilateral nephrocalcinosis with renal atrophy and renal loss of  $Mg^{2+}$  and  $Ca^{2+}$  were found in all patients.

Hypomagnesemia persisted despite oral supplementation and was accompanied by hypokalemia in two individuals. Despite progressive renal failure, calciuria remained high. Although thiazide-diuretic intake lowered calciuria by 50% in one patient, serum  $Mg^{2+}$  remained unchanged. Hypocitraturia was identified in all patients and hyperchloremic acidosis in one. Serum phosphorus was within the normal range in all patients. In two sisters with early diagnosis of nephrocalcinosis, measurements of urinary oxalate level and activity and immunoblotting of alanine-glyoxylate aminoacid transferase from a liver biopsy excluded the hypothesis of primary oxalosis.

Slope of renal decline was heterogeneous among patients. Although one patient had stable estimated GFR (eGFR) between the age 16 and 17 years (51 ml/min per 1.73 m<sup>2</sup>), two patients reached ESRD at the age of 16 and 22 years after a progressive decrease in eGFR. Renal transplantation was performed in these latter patients. On a calcineurin inhibitor-based immunosuppressive regimen,  $Mg^{2+}$  and  $Ca^{2+}$  renal excretion were normal. Early and severe tertiary hyperparathyroidism occurred in both patients and required surgery. Mild nephrocalcinosis was observed upon 1-year renal biopsy in one patient but was absent in the other 6 years after renal transplantation.

In all patients, various ocular abnormalities of mild to moderate severity were identified, including pigmentary maculopathy, strabismus, iris colobomata, myopia, and nystagmus. However, none had severe visual impairment and asymptomatic pigmentary maculopathy was the only finding in one individual.

Last, two patients presented neuromuscular disorders (muscular-exercise intolerance characterized by limb stiffness and pain occurring a few minutes after beginning exercise in one and progressive weakness and abundant cramps in the other) having begun at age 14 and 21. A needle electromyography showed neither nerve conduction defect nor myotonic or paramyotonic abnormalities. Muscle-channel dysfunction was thus explored by recording surface compound motor action potential (CMAP) changes after

exercise tests (repeating short exercises at room temperature and, after cooling, an extended period of exercise, as described by Fournier *et al.* [13]). CMAP amplitude correlates with the number of functional muscle fibers. Its decrease is an index of muscle weakness experienced after exercise. In our patients short exercise did not induce significant CMAP changes, whereas longer-duration exercise was followed by a transient 20% to 40% decrease in the amplitude of CMAP starting at 10 minutes after the end of the exercise (Figure 1). In one patient, CMAP decrease occurred while serum  $Mg^{2+}$  and  $K^+$  were in the normal range (posttransplant period). Autoimmune disease, viral infection, and drug or heavy metal toxicity were ruled out.

Parents of patients F1.3 and F1.4 could not be tested but were free of urolithiasis and/or urinary infections. In the parents of F2.3, biologic tests showed normal serum  $Mg^{2+}$  levels (0.78 and 0.85 mmol/L, respectively) but identified hypercalciuria (urinary  $Ca^{2+}$ /creatinine ratio of 2.8 and 0.6 mg/mg, respectively [ $n < 0.4$ ]) and mild chronic kidney disease (eGFR estimated by the simplified Modifications of Diet in Renal Disease formula of 57.8 and 56.1 ml/min per 1.73 m<sup>2</sup>). No other renal, ocular, or neurologic manifestations were found. All parents declined genetic analysis.

Typical renal features of FHHNC and recessive inheritance of the disease prompted us to test *CLDN16* and *CLDN19* in both families. Direct sequencing of *CLDN19* identified two different heterozygous missense mutations within exon 1 (c.59G>A, p.Gly20Asp and c.130G>A, p.Val44Met) in patient F1.3 and a homozygous missense mutations within exon 1 (c.59G>A, p.Gly20Asp) in patient F2.3. Mutation of *CLDN16* was ruled out and genetic counseling was provided. Genotyping of *CLDN16* and *CLDN19* could not be performed in patient F1.4 but was deduced from her highly suggestive phenotype and the genotyping of her sister (patient F1.3).

## Discussion


Herein, we reported on three patients harboring *CLDN19* mutations. Mutations in *CLDN16* and *CLDN19*, the genes encoding for two structural proteins of the tight junction (claudin-16 and claudin-19, respectively), have been previously identified in patients with FHHNC (2,3,5). In epithelial cells, claudin-16 (a  $Na^+$ -channel) and claudin-19 (a  $Cl^-$ -blocker) interact to form heteromultimers and generate a cation-selective tight junction that regulates paracellular  $Mg^{2+}$  and  $Ca^{2+}$  permeability (6). In mice kidneys, *Cldn16* and *Cldn19* are mainly expressed in the ascending loop of Henle (and to a lesser extent in the distal convoluted tubule) (5,14).

In our patients, direct sequencing of *CLDN19* identified a sequence variation previously identified in patients with FHHNC and severe ocular involvement (p.Gly20Asp) and known to be responsible for a mislocalization of the claudin-19 mutant in epithelial cells (5). Whereas one patient harbored a homozygous p.Gly20Asp variant, the

**Table 1. Phenotypic characteristics of three individuals with *CLDN19* mutation**

Characteristic	Patient			Normal Values
	F1.3	F1.4	F2.3	
Gender	Female	Female	Female	
Mutation	p.Gly20Asp/p.Val44Met	p.Gly20Asp/p.Val44Met	p.Gly20Asp/p.Gly20Asp	
Age at renal symptoms onset, years	10	0.9	16	
Age at tests, years	16	13	16	
Organ involvement	UTI, NL, NC PM, Strab, nystagmus Muscular-exercise intolerance	UTI, NL, NC PM No	NC Strab, Myopia, Ir colobomata Muscular exercise intolerance	
Blood tests				
SCr, $\mu\text{mol/L}$	180	200	123	
inulin clearance, ml/min per 1.73 m <sup>2</sup>	—	—	48.8	
eGFR (sMDRD), ml/min per 1.73 m <sup>2</sup>	29	30	53.7	
Mg <sup>2+</sup> , mmol/L	—	—	0.59	0.73 to 1.06
K <sup>+</sup> , mmol/L	3.5	3.3	3.7	3.5 to 5
HCO <sub>3</sub> <sup>-</sup> , mmol/L	23	17	28	21 to 30
Ca <sup>2+</sup> , mmol/L	2.1	1.84	2.35	2.2 to 2.6
PO <sub>4</sub> <sup>3-</sup> , mmol/L	1.32	1.74	0.82	0.8 to 1.5
25(OH)vitamin D <sub>3</sub> , ng/ml	—	—	13.3	9 to 45
1,25(OH) <sub>2</sub> vitamin D <sub>3</sub> , pg/ml	—	—	69	18 to 60
IPTH, pg/ml	—	150	155	15 to 85
alkaline phosphatase, IU/L	207	656	208	100 to 280
Urinary tests				
FeMg <sup>2+</sup> , % <sup>a</sup>	—	—	9.9	<2%
Ca <sup>2+</sup> /Cr ratio, mg/mg	0.9	1.2	0.9	<0.4
TmPO <sub>4</sub> <sup>3-</sup> , %	—	—	83.5	>85
citrate, mg/24 h	101	285	362.4	400 to 900
oxalate, $\mu\text{mol}/24\text{ h}$	186	163	232.8	200 to 450
pH (nocturnal)	—	—	6.36	
proteinuria, mg/24 h	—	—	510	<300
hematuria, (0 to 3+)	0	0	0	
drug intake	Calcium pyridoxine	Calcium pyridoxine	No	
Renal outcome	ESRD (at age 22)	ESRD (at age 16)	51 (at age 17)	
eGFR (sMDRD)				

UTI, urinary-tract infection; NL, nephrolithiasis; NC, nephrocalcinosis; SCr, serum creatinine; PM, pigmentary maculopathy; Strab, strabismus; Ir, Iris; sMDRD, standard Modifications of Diet in Renal Disease equation; TmPO<sub>4</sub><sup>3-</sup>, maximum rate of renal tubular reabsorption of phosphate.  
<sup>a</sup>FeMg<sup>2+</sup> was calculated as follows: *urinary/plasma* [Mg<sup>2+</sup>]/*urinary/plasma* [creatinine].



**Figure 1. | Electrophysiological characteristics after prolonged exercise in two patients with *CLDN19* mutations.** The amplitude of CMAP was significantly decreased after exercise that lasted 5 minutes (according to Fournier *et al.* [13]). The amplitude of CMAP, recorded from the abductor digiti minimi muscle from 0 to 40 minutes after exercise, is expressed as a percentage of the pre-exercise value. In Patient F1.3, tests were performed while serum  $Mg^{2+}$  and  $K^+$  levels were normalized.


two other sisters were compound heterozygous for missense mutations in *CLDN19* (Gly20Asp and p.Val44Met). Val44 is a neutral amino acid that has been highly conserved throughout evolution until Fugu fish (see genomic alignment of *CLDN19* in seven mammals in Figure 2B from the Ensembl database) and is located within the claudin-specific amino-acid motif W-GLW-C-C (see Figure 2A). Also, the p.Val44Met mutation was not found in 150 control chromosomes from the same geographic origin. In patient F1.3, a concomitant mutation of *CLDN16* was ruled out, thus reinforcing the probability of the pathogenic status of the p.Val44Met variant.

In this series, blood and urinary tests confirmed the usual features of FHHNC (15) in *CLDN19* patients: (1) persistent hypomagnesemia unresponsive to  $Mg^{2+}$  administration, (2) thiazide-sensitive hypercalciuria with normal serum  $Ca^{2+}$  levels and a slightly increased parathormone level, (3) low urinary citrate excretion, and (4) progressive renal failure leading to ESRD. However, one can note some peculiar renal findings. First, although FHHNC is mostly diagnosed during the first years of life (age of diagnosis within the first decade for all patients, within the first year of life for 8 of 12 patients) (5), it can be asymptomatic until the end of the second decade as exemplified by patient F2.3. In patients with *CLDN16*-related FHHNC, a genotype-phenotype correlation has been established and age at onset and severity may be predicted from the *CLDN16* genotype (12). Because of the recent recognition of *CLDN19* mutations in humans and their low frequency, this analysis has not yet been performed in patients with *CLDN19* mutations. Second, in patient F2.3, calciuria returned to normal values after 1 year of thiazide-diuretic intake, which is an unusual finding (15). Serum  $Mg^{2+}$  level was not modified. Whether thiazide diuretics may counteract renal loss of  $Ca^{2+}$  in *CLDN19* patients remains to be clarified. Last, hypokalemia occurred in two patients despite a worsening in GFR (in the ab-

sence of diuretic intake, vomiting, or diarrhea). Refractory hypokalemia and  $K^+$  depletion are frequently associated with  $Mg^{2+}$  deficiency irrespective of its mechanism and may persist until  $Mg^{2+}$  deficiency is restored (16). It is thus tempting to speculate that the renal loss of  $K^+$  in adulthood might be related to chronic  $Mg^{2+}$  deficiency. Alternatively, future studies should test whether expression of genes involved in the molecular mechanisms of renal  $K^+$  handling are modified by *CLDN19* mutations.

Time from diagnosis of nephrocalcinosis and ESRD was 12 and 16 years. After renal transplantation,  $Ca^{2+}$  and  $Mg^{2+}$  handling was normalized. Renal  $Ca^{2+}$  deposits identified 1 year after renal transplantation in patient F1.3 were probably related to the severe hyperparathyroidism. Moreover, long-term renal biopsy failed to identify nephrocalcinosis confirming the absence of posttransplantation recurrence of FHHNC. It also underlines the need for genetic screening before kidney transplantation in patients with nephrocalcinosis to rule out other causes of congenital nephrocalcinosis such as primary hyperoxaluria. In conclusion, the renal phenotype of *CLDN19* mutations closely mimics the kidney involvement observed in *CLDN16* patients: Nephrocalcinosis with renal atrophy, renal  $Mg^{2+}$  and  $Ca^{2+}$  wasting, and progressive renal decline, which is sometimes accompanied by incomplete distal tubular acidosis and hypokalemia (10).

In our study, the genotype of parents was unknown, but we could show that individuals F2.1 and F2.2, who were likely to be heterozygous for the *CLDN19* variant, had hypercalciuria and moderate chronic kidney disease (stage 3) but no hypomagnesemia. Extrarenal features were absent. These data



**Figure 2. | (A) Localization of *CLDN19* mutations on the predicted model of claudin-19.** The Val44 residue is localized within the claudin-specific W-GLW-C-C motif. (B) Genomic alignment around the Val44 (V) residue of *CLDN19* of seven mammalian species (from the Ensembl database).

are consistent with previous reports, and heterozygous mutations of *CLDN19* and *CLDN16* are now recognized as risk factors for hypercalciuria and kidney stones (5,10,15). Although a common polymorphism in the *CLDN14* gene has been associated with the occurrence of kidney stones and increased urinary  $\text{Ca}^{2+}$  levels (17), the role of *CLDN16* and *CLDN19* polymorphisms in hypercalciuria and/or kidney stones in the general population is unknown and remain to be assessed.

In contrast to *CLDN16* patients, all *CLDN19* patients previously reported had severe ocular involvement associated with near blindness: macular colobomata, myopia, and horizontal nystagmus were identified in 50%, 83%, and 91% of tested patients (5). In the eye of zebrafish, *CLDN19* is specifically expressed in the retina, mainly in the retinal pigment epithelium (5). Its function in this epithelium remains unknown, but effective tight junction formation is required during normal retinal development (18). In our study, all patients had ocular involvement; however, its severity was far less significant. Only one patient had mild visual loss (F1.4) and retinal-pigment maculopathy was found incidentally in one. Thus, accurate ophthalmological examination is required in all patients with FHHNC, even in the absence of visual loss. Moreover, genetic testing of *CLDN19* should be considered in FHHNC patients with ocular involvement, even if symptoms are subtle.

Herein, we described, for the first time, the electrophysiological characteristics of neuromuscular involvement in *CLDN19* patients. Two of the three patients described had similar muscular-exercise intolerance with limb stiffness and cramps. Electrophysiological exploration revealed a similar response after tests: Short exercise at room temperature or after cooling induced no significant changes of CMAP amplitude, whereas CMAP amplitude was significantly decreased 10 to 15 min after sustained exercise. Exercise acts as provocative tests and provides information on the ability of active fibers to depolarize and repolarize. Abnormal CMAP amplitude is observed in approximately 70% to 80% of patients with periodic paralysis (19,20). The electrophysiological pattern observed in our patients (pattern V; CMAP declines after long exercise without preliminary increment) is more frequently associated with mutations in  $\text{Ca}^{2+}$  or  $\text{K}^{+}$  channel *CACNA1A*, *KCNJ2*, and *SCN4A* genes (13,21,22). Whether isolated neuromuscular defects may be induced by some *CLDN19* mutations thus accounting for channelopathies of unknown origin remains to be tested. Of note, these abnormalities were identified in patient F1.3 while serum  $\text{Mg}^{2+}$  and  $\text{K}^{+}$  levels were normalized (posttransplant period), suggesting that mutations of *CLDN19* are directly responsible for the neuromuscular disorders. Last, noninvasive the electromyography techniques that we used failed to detect a decrease in muscle conduction velocities, a frequent finding in  $\text{Ca}^{2+}$  channel mutations (23,24). Invalidation of *Cldn19* in mice leads to ambulatory disturbances,

which is, in part, secondary to the disappearance of tight junctions from myelinated Schwann cells in the peripheral nerves where *Cldn19* is expressed (25). The presence of a skeletal muscle channelopathy has not been explored in these mice, and muscular expression of *Cldn19* remains unknown. In our patients, no change in nerve conductance was observed. Because accurate assessment of neuromuscular status in *CLDN16* patients has not been performed and subtle abnormalities could have been missed, whether this finding is specific of *CLDN19* patients needs to be confirmed.

In summary, mutations of *CLDN19* lead to recessively inherited hypomagnesemia, hypercalciuria with nephrocalcinosis, and progressive renal decline. Extrarenal features include ocular manifestations, with or without visual impairment, and muscular-exercise intolerance partly mimicking periodic paralysis (*i.e.*, channelopathies). Age at onset and severity are heterogeneous among families. Further studies are required to assess a potential genotype-phenotype correlation, as has been previously recognized in patients with *CLDN16* mutations.

#### Disclosures

None.

#### References

1. Wrong O: Nephrocalcinosis. In: *Oxford Textbook of Clinical Nephrology*, edited by Davison AM, Cameron JS, Grunfeld J, Oxford, United Kingdom, Oxford University Press, 2005, pp 1375–1396
2. Simon DB, Lu Y, Choate KA, Velazquez H, Al-Sabban E, Praga M, Casari G, Bettinelli A, Colussi G, Rodriguez-Soriano J, McCredie D, Milford D, Sanjad S, Lifton RP: Paracellin-1, a renal tight junction protein required for paracellular  $\text{Mg}^{2+}$  resorption. *Science* 285: 103–106, 1999
3. Weber S, Hoffmann K, Jeck N, Saar K, Boeswald M, Kuwertz-Broeking E, Meij IJ, Knoers NV, Cochat P, Sulakova T, Bonzel KE, Soergel M, Manz F, Schaerer K, Seyberth HW, Reis A, Konrad M: Familial hypomagnesaemia with hypercalciuria and nephrocalcinosis maps to chromosome 3q27 and is associated with mutations in the PCLN-1 gene. *Eur J Hum Genet* 8: 414–422, 2000
4. Weber S, Schlingmann KP, Peters M, Nejsum LN, Nielsen S, Engel H, Grzeschik KH, Seyberth HW, Grone HJ, Nusing R, Konrad M: Primary gene structure and expression studies of rodent paracellin-1. *J Am Soc Nephrol* 12: 2664–2672, 2001
5. Konrad M, Schaller A, Seelow D, Pandey AV, Waldegger S, Lesslauer A, Vitzthum H, Suzuki Y, Luk JM, Becker C, Schlingmann KP, Schmid M, Rodriguez-Soriano J, Ariceta G, Cano F, Enriquez R, Juppner H, Bakkaloglu SA, Hediger MA, Gallati S, Neuhauss SC, Nurnberg P, Weber S: Mutations in the tight-junction gene claudin 19 (*CLDN19*) are associated with renal magnesium wasting, renal failure, and severe ocular involvement. *Am J Hum Genet* 79: 949–957, 2006
6. Hou J, Renigunta A, Konrad M, Gomes AS, Schneeberger EE, Paul DL, Waldegger S, Goodenough DA: Claudin-16 and claudin-19 interact and form a cation-selective tight junction complex. *J Clin Invest* 118: 619–628, 2008
7. Gunzel D, Haisch L, Pfaffenbach S, Krug SM, Milatz S, Amasheh S, Hunziker W, Muller D: Claudin function in

- the thick ascending limb of Henle's loop. *Ann NY Acad Sci* 1165: 152–162, 2009
8. Gunzel D, Yu AS: Function and regulation of claudins in the thick ascending limb of Henle. *Pflugers Arch* 458: 77–88, 2009
  9. Alexander RT, Hoenderop JG, Bindels RJ: Molecular determinants of magnesium homeostasis: Insights from human disease. *J Am Soc Nephrol* 19: 1451–1458, 2008
  10. Weber S, Schneider L, Peters M, Misselwitz J, Ronnefarth G, Boswald M, Bonzel KE, Seeman T, Sulakova T, Kuwertz-Broking E, Gregoric A, Palcoux JB, Tasic V, Manz F, Scharer K, Seyberth HW, Konrad M: Novel paracellin-1 mutations in 25 families with familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 12: 1872–1881, 2001
  11. Benigno V, Canonica CS, Bettinelli A, von Vigier RO, Truttmann AC, Bianchetti MG: Hypomagnesaemia-hypercalciuria-nephrocalcinosis: A report of nine cases and a review. *Nephrol Dial Transplant* 15: 605–610, 2000
  12. Konrad M, Hou J, Weber S, Dotsch J, Kari JA, Seeman T, Kuwertz-Broking E, Peco-Antic A, Tasic V, Dittrich K, Alshaya HO, von Vigier RO, Gallati S, Goodenough DA, Schaller A: CLDN16 genotype predicts renal decline in familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *J Am Soc Nephrol* 19: 171–181, 2008
  13. Fournier E, Arzel M, Sternberg D, Vicart S, Laforet P, Eymard B, Willer JC, Tabti N, Fontaine B: Electromyography guides toward subgroups of mutations in muscle channelopathies. *Ann Neurol* 56: 650–661, 2004
  14. Angelow S, El-Husseini R, Kanzawa SA, Yu AS: Renal localization and function of the tight junction protein, claudin-19. *Am J Physiol Renal Physiol* 293: F166–F177, 2007
  15. Praga M, Vara J, Gonzalez-Parra E, Andres A, Alamo C, Araque A, Ortiz A, Rodicio JL: Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. *Kidney Int* 47: 1419–1425, 1995
  16. Huang C, Kuo E: Mechanism of hypokalemia in magnesium deficiency. *J Am Soc Nephrol* 18: 2649–2652, 2007
  17. Thorleifsson G, Holm H, Edvardsson V, Walters GB, Styrkarsdottir U, Gudbjartsson DF, Sulem P, Halldorsson BV, de Vegt F, d'Ancona FC, den Heijer M, Franzson L, Christiansen C, Alexandersen P, Rafnar T, Kristjansson K, Sigurdsson G, Kiemenev LA, Bodvarsson M, Indridason OS, Palsson R, Kong A, Thorsteinsdottir U, Stefansson K: Sequence variants in the CLDN14 gene associate with kidney stones and bone mineral density. *Nat Genet* 41: 926–930, 2009
  18. Rahner C, Fukuhara M, Peng S, Kojima S, Rizzolo LJ: The apical and basal environments of the retinal pigment epithelium regulate the maturation of tight junctions during development. *J Cell Sci* 117: 3307–3318, 2004
  19. Kuntzer T, Flocard F, Vial C, Kohler A, Magistris M, Labarre-Vila A, Gonnard PM, Ochsner F, Soichot P, Chan V, Monnier G: Exercise test in muscle channelopathies and other muscle disorders. *Muscle Nerve* 23: 1089–1094, 2000
  20. McManis PG, Lambert EH, Daube JR: The exercise test in periodic paralysis. *Muscle Nerve* 9: 704–710, 1986
  21. Venance S, Cannon SC, Fialho D, Fontaine B, Hanna MG, Ptacek LJ, Tristani-Firouzi M, Tawil R, Griggs RC, and the CINCH investigators: The primary periodic paralyses: Diagnostics, pathogenesis and treatment. *Brain* 129: 8–17, 2006
  22. Bendahhou S, Fournier E, Sternberg D, Bassez G, Furby A, Sereni C, Donaldson MR, Larroque MM, Fontaine B, Barhanin J: *In vivo* and *in vitro* functional characterization of Andersen's syndrome mutations. *J Physiol* 565: 731–741, 2005
  23. Zwarts MJ, van Weerden TW, Links TP, Haenen HT, Oosterhuis HJ: The muscle fiber conduction velocity and power spectra in familial hypokalemic periodic paralysis. *Muscle Nerve* 11: 166–173, 1988
  24. Links TP, van der Hoeven JH: Muscle fiber conduction velocity in arg1239his mutation in hypokalemic periodic paralysis. *Muscle Nerve* 23: 296, 2000
  25. Miyamoto T, Morita K, Takemoto D, Takeuchi K, Kitano Y, Miyakawa T, Nakayama K, Okamura Y, Sasaki H, Miyachi Y, Furuse M, Tsukita S: Tight junctions in Schwann cells of peripheral myelinated axons: A lesson from claudin-19-deficient mice. *J Cell Biol* 169: 527–538, 2005

**Received:** March 30, 2010 **Accepted:** September 15, 2010

Published online ahead of print. Publication date available at [www.cjasn.org](http://www.cjasn.org).